Osaka – An Osaka University research team said Monday it has concluded that the world’s first clinical trial, spanning over years, transplanting corneal tissues derived from induced pluripotent stem cells, or iPS cells, into four almost-blind patients was safe and effective.
None of the patients experienced rejection or tumorigenicity of the transplanted cells and all saw improvements in their symptoms, according to the team at Osaka University led by professor Koji Nishida.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.
We humbly apologize for the inconvenience.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.